Journal of Neurology

, Volume 259, Issue 7, pp 1312–1316 | Cite as

Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis

  • Fredrik RomiEmail author
  • Shigeaki Suzuki
  • Norihiro Suzuki
  • Axel Petzold
  • Gordon T. Plant
  • Nils Erik Gilhus
Original Communication


Myasthenia gravis (MG) is an autoimmune disease characterized by skeletal muscle weakness mainly caused by acetylcholine receptor antibodies. MG can be divided into generalized and ocular, and into early-onset (<50 years of age) and late-onset (≥50 years of age). Anti-Kv1.4 antibodies targeting α-subunits (Kv1.4) of the voltage-gated potassium K+ channel occurs frequently among patients with severe MG, accounting for 18% of a Japanese MG population. The aim of this study was to characterize the clinical features and serological associations of anti-Kv1.4 antibodies in a Caucasian MG population with mild and localized MG. Serum samples from 129 Caucasian MG patients with mainly ocular symptoms were tested for the presence of anti-Kv1.4 antibodies and compared to clinical and serological parameters. There were 22 (17%) anti-Kv1.4 antibody-positive patients, most of them women with late-onset MG, and all of them with mild MG. This contrasts to the Japanese anti-Kv1.4 antibody-positive patients who suffered from severe MG with bulbar symptoms, myasthenic crisis, thymoma, myocarditis and prolonged QT time on electrocardiography, despite equal anti-Kv1.4 antibody occurrence in both populations. No other clinical or serological parameters influenced anti-Kv1.4 antibody occurrence.


Myasthenia gravis Anti-Kv1.4 antibodies 



Acetylcholine receptor




Generalized MG


Heat shock protein


Potassium K+ channel α-subunit


Myasthenia gravis


Matrix metalloproteinases


Magnetic resonance imaging


Muscle specific kinase


Ocular MG


Voltage-gated potassium K+ channel



This work was supported a grant from the Japanese Ministry of Education, Science, Sports and Culture (no. 23591255) and a Neuroimmunological Disease Research Committee grant from the Japanese Ministry of Health, Labour, and Welfare.

Conflicts of interest



  1. 1.
    Lindstrøm JM, Seybold ME, Lennon VA, Whittingham S, Duane DD (1998) Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975 classical article. Neurology 51:933–939PubMedGoogle Scholar
  2. 2.
    Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P (2001) Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 11:208–216PubMedCrossRefGoogle Scholar
  3. 3.
    Luchanok U, Kaminski HJ (2008) Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 21:8–15PubMedCrossRefGoogle Scholar
  4. 4.
    Wilcox N (1993) Myasthenia gravis. Curr Opin Immunol 5:910–917CrossRefGoogle Scholar
  5. 5.
    Li Z, Forester N, Vincent A (1996) Modulation of acetylcholine receptor function in TE671 (rhabdomyocyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis. J Neuroimmunol 64:179–183PubMedCrossRefGoogle Scholar
  6. 6.
    Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368PubMedCrossRefGoogle Scholar
  7. 7.
    McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55:580–584PubMedCrossRefGoogle Scholar
  8. 8.
    Fuhrer C, Sugiyama JE, Taylor RG, Hall ZW (1997) Association of muscle-specific kinase MuSK with the acetylcholine receptor in mammalian muscle. EMBO J 16:4951–4960PubMedCrossRefGoogle Scholar
  9. 9.
    Borges LS, Ferns M (2001) Agrin-induced phosphorylation of the acetylcholine receptor regulates cytoskeletal anchoring and clustering. J Cell Biol 153:1–12PubMedCrossRefGoogle Scholar
  10. 10.
    Romi F, Gilhus NE, Luckman S (2008) Serum matrix metalloproteinase-3 (MMP-3) levels are elevated in myasthenia gravis. J Neuroimmunol 195:96–99PubMedCrossRefGoogle Scholar
  11. 11.
    Helgeland G, Petzold A, Luckman SP, Gilhus NE, Plant GT, Romi F (2011) Matrix metalloproteinases in myasthenia gravis. Eur Neurol 65:53–58PubMedCrossRefGoogle Scholar
  12. 12.
    Romi F, Skeie GO, Gilhus NE, Aarli JA (2005) Striational antibodies in myasthenia gravis: reactivity and possible clinical significance. Arch Neurol 62:442–446PubMedCrossRefGoogle Scholar
  13. 13.
    Helgeland G, Petzold A, Hoff JM, Gilhus NE, Plant GT, Romi FR (2010) Anti-heat shock protein 70 antibody levels are increased in myasthenia gravis and Guillain-Barré syndrome. J Neuroimmunol 225:180–183PubMedCrossRefGoogle Scholar
  14. 14.
    Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain 133(9):2734–2748PubMedCrossRefGoogle Scholar
  15. 15.
    Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9(8):776–785PubMedCrossRefGoogle Scholar
  16. 16.
    Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ (2008) Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 70(20):1883–1890PubMedCrossRefGoogle Scholar
  17. 17.
    Suzuki S, Utsugisawa K, Nagane Y, Suzuki N (2011) Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011:740583PubMedGoogle Scholar
  18. 18.
    Yellen G (2002) The voltage-gated potassium channels and their relatives. Nature 419:35–42PubMedCrossRefGoogle Scholar
  19. 19.
    Suzuki S, Satoh T, Yasuoka H, Hamaguchi Y, Tanaka K, Kawakami Y, Suzuki N, Kuwana M (2005) Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis. J Neuroimmunol 170(1–2):141–149PubMedCrossRefGoogle Scholar
  20. 20.
    Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475–490PubMedCrossRefGoogle Scholar
  21. 21.
    Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N (2011) Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 230(1–2):148–152PubMedCrossRefGoogle Scholar
  22. 22.
    Wickenden AD, Jegla TJ, Kaprielian R, Backx PH (1999) Regional contributions of KV1.4, KV4.2, and KV4.3 to transient outward K+ current in rat ventricle. Am J Physiol 276:H1599–H1607PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Fredrik Romi
    • 1
    Email author
  • Shigeaki Suzuki
    • 2
  • Norihiro Suzuki
    • 2
  • Axel Petzold
    • 3
    • 4
  • Gordon T. Plant
    • 5
    • 6
    • 7
  • Nils Erik Gilhus
    • 1
    • 8
  1. 1.Department of NeurologyHaukeland University HospitalBergenNorway
  2. 2.Department of NeurologyKeio University School of MedicineTokyoJapan
  3. 3.Department of NeuroimmunologyUCL Institute of NeurologyLondonUK
  4. 4.Department of NeurologyFree University Medical CenterAmsterdamThe Netherlands
  5. 5.National Hospital for Neurology and NeurosurgeryLondonUK
  6. 6.Department of Neuro-OphthalmologyMoorfields Eye HospitalLondonUK
  7. 7.Medical Eye UnitSt. Thomas’ HospitalLondonUK
  8. 8.Department of Clinical MedicineUniversity of BergenBergenNorway

Personalised recommendations